New drug policy in childhood obesity

International Journal of Obesity

Volumn 29, Issue , 2005, Pages S62-S65

  Molnar D ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Childhood obesity; Pharmacotherapy

Indexed keywords

2 (3,5 DIFLUOROPHENYL) 3,5 DIMETHYL 2 MORPHOLINOL; AMYLASE INHIBITOR; ANOREXIGENIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; CANNABINOID RECEPTOR ANTAGONIST; CARBOXYPEPTIDASE INHIBITOR; CORTICOTROPIN RELEASING FACTOR DERIVATIVE; ENZYME INHIBITOR; GASTROINTESTINAL AGENT; GROWTH HORMONE DERIVATIVE; HORMONE ANTAGONIST; HORMONE DERIVATIVE; LEPTIN; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NORADRENALIN UPTAKE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RIMONABANT; SIBUTRAMINE; SOMATOSTATIN DERIVATIVE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; ZONISAMIDE;

CLINICAL TRIAL; CONSTIPATION; DEFECATION HABIT; EUROPE; FECAL URGENCY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TACHYCARDIA; UNITED STATES; VITAMIN DEFICIENCY; XEROSTOMIA;

ADOLESCENT; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CHILD; CYCLOBUTANES; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; HUMANS; LACTONES; LIPASE; OBESITY;

EID: 33644971646     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803084     Document Type: Article

References (35)

1. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999– 2000. JAMA 2002; 288: 1728–1732.
2. Booth ML, Wake M, Armstrong T, Chey T, Hesketh K, Mathur S. The epidemiology of overweight and obesity among Australian children and adolescents, 1995–97. Aust NZ J Public Health 2001; 25: 162–169.
3. Watkins DC, Murray LJ, McCarron P, Boreham CAG, Cran GW, Young IS, McGartland C, Robson PJ, Savage JM. Ten-year trends for fatness in Northern Irish adolescents: The Young Hearts ProjectsFrepeat cross-sectional study. Int J Obes Relat Metab Disord 2005; 29: 579–585.
4. Al-Haddad FH, Little BB, Abdul Ghafoor AG. Childhood obesity in United Arab Emirates schoolchildren: A national study. Ann Hum Biol 2005; 32: 72–79.
5. Epstein LH, Valoski AM, Kalarchian MA, McCurley J. Do children lose and maintain weight easier than adults: A comparison of child and parent weight changes from six months to ten years. Obes Res 1995; 3: 411–417.
6. Epstein LH, Valoski AM, Wing RR, McCurley J. Ten-yer outcomes of behavioural family-based treatment for childhood obesity. Health Psychol 1994; 13: 373–383.
7. Finer N. Present and future pharmacologic approaches. Brit Med Bull 1997; 53: 409–432.
8. Ryan DH, Kaiser P, Bray GA. Sibutramine: A novel new agent for obesity treatment. Obes Res 1995; 3 (Supplement 4): 553–559.
9. James WTP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WHM, VanGaal LF. Effect of Sibutramine on weight maintenance after weight loss: A randimized trial. Lancet 2000; 356: 2119–2125.
10. Wirth A, Krause J. Long-term weight loss with sibutramine. JAMA 2001; 286: 1331–1339.
11. Dujovne CA, Zavoral JH, Rowe E, Memdel CM. Effects of sibutramine on body weight and serum lipids. Am Heart J 2001; 142: 489–497.
12. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type diabetes: A randomised, double-blind, placebo controlled study. Diabet Obes Metab 2000; 2: 105–112.
13. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: A meta-analysis of controlled trials. Obes Res 2003; 11: 1116–1123.
14. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity. JAMA 2003; 289: 1805–1812.
15. Godoy-Matos A, Carraro L, Vieira A, Oliviera A, Gues EP, Mattos L, Rangel C, Moreira RO, Coutimho W, Appolinario JC. Treatment of adolescents with sibutramine: A randomised, douleblind, controlled study. J Clin Endocrinol Metab 2005; 90: 1460– 1465.
16. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21 (Supplement 3): S12–S23.
17. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, Krempf M. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 160–161.
18. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JPH, Sjostrom L. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321–1326.
19. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49–61.
20. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002; 10: 642–650.
21. Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004; 163: 738–741.
22. Norgren S, Danielsson P, Jurold R, Lotborn M, Marcus C. Orlistat treatment in obese prepubertal children: Pilot study. Acta Paediatr 2003; 92: 666–670.
23. Chanoine JP, Hauptman J, Boldrin M, Smith D, Hampl S. Beneficial effects of orlistat on weight and body composition in obese adolescents. Int J Obes Relat Metab Disord 2004; 28 (Supplement 1): S195.
24. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effects of orlistat on weight and body composition in obese adolescents: A randomised controlled trial. JAMA 2005; 293: 2873–2883.
25. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12: 1197–1211.
26. Astrup A, Toubro S. Topiramate: A new potential pharmacological treatment for obesity. Obes res 2004; 12: 167S–173S.
27. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabionid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1363–1364.
28. Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV. Leptin: The tale of an obesity gene. Diabetes 1996; 45: 1455–1462.
29. Dallongeville J, Fruchart J-Ch, Auwerx J. Leptin, a pleiotropic hormone: Physiology, pharmacology, and strategies for discovery of leptin modulators. J Med Chem 1998; 41: 5337–5352.
30. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O’Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879–884.
31. Pérusse L, Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Snyder EE, Bouchard C. The human obesity gene map: The 2004 update. Obes Res 2005; 13: 381–490.
32. Gibson WT, Farooqi IS, Moreau M, DePaoli AM, Lawrence E, O’Rahilly S, Trussell RA. Congenital leptin deficiency due to homozygosity for the delta133G mutation: Report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab 2004; 89: 4821–4826.
33. Heymsfield SB, Greenberg AS, Fujoka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCanish M. Recombinant leptin for weight loss in obese and lean adults. JAMA 1999; 282: 1568–1575.
34. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, farid AR, Smith FJ, Campfield LA. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85: 4003–4009.
35. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: A randomized, dose-ranging study. JAMA 2003; 289: 1826–1832.